If you are interested in learning
more about collaboration opportunities with Seattle Genetics, please contact our Business Development team. We are also actively evaluating potential in-licensing opportunities for cancer therapeutics.
Email Business Development,
or call 425-527-4000.
Seattle Genetics' proprietary sugar-engineered antibody (SEA) technology is a novel approach to increasing the potency of monoclonal antibodies that is complementary to our ADC technology.
SEA technology produces a non-fucosylated engineered antibody, resulting in an enhanced innate immune response. A key feature of our SEA technology is that no genetic modification of the antibody-producing cell line is necessary and standard cell culture conditions can be used, while maintaining the underlying manufacturing processes, yields and product quality. We believe the SEA approach is much simpler and more cost-effective to implement as compared to existing technologies for enhancing antibody effector function, most of which require development of new cell lines.
The first antibody that we have developed using our SEA technology is SEA-CD40. This antibody undergoes conditional activation upon crosslinking. Our preclinical studies show that the non-fucosylated antibody is a potent stimulator of immune cells that may be able to harness the power of a patients’ own immune system to fight their cancer. A phase 1 clinical trial of SEA-CD40 for solid tumors is expected to be initiated in 2015.